The FDA has approved olmesartan medoxomil/amlodipine/hydrochlorothiazide (Tribenzor), a three-in-one combination product taken once-daily for the treatment of hypertension in patients who are not adequately controlled on the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers and diuretics.

Administered as a fixed-dose combination treatment, Tribenzor, which is not indicated for initial therapy, combines the actions of olmesartan medoxomil (which blocks angiotensin II receptors), amlodipine (which inhibits the entrance of calcium into the blood vessel walls) and hydrochlorothiazide (a diuretic which reduces water volume in the blood).